Compass Therapeutics And 2 More Compelling Penny Stocks

As the U.S. markets navigate a period of volatility, with the S&P 500 and Nasdaq recently closing higher despite economic uncertainties, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or emerging companies, continue to capture interest due to their affordability and growth potential. While the term may seem outdated, these stocks can offer significant value when backed by strong financials and clear growth strategies. In this article, we explore three compelling penny stocks that stand out for their financial strength and long-term prospects.

Top 10 Penny Stocks In The United States

Click here to see the full list of 757 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Compass Therapeutics (NasdaqCM:CMPX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology and other diseases, with a market cap of $262.74 million.

Operations: The company generates revenue of $0.85 million from its biotechnology startup segment.

Market Cap: $262.74M

Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, is currently pre-revenue with earnings results showing a net loss of US$49.38 million for 2024. Recent announcements highlight statistically significant top-line data from the COMPANION-002 trial for tovecimig in combination with paclitaxel in advanced biliary tract cancer (BTC), showing an improved overall response rate compared to paclitaxel alone. The company's financial stability is supported by sufficient cash runway and no debt, although high share price volatility remains a concern. The management team has limited tenure, which may impact strategic execution going forward.

• Click here to discover the nuances of Compass Therapeutics with our detailed analytical financial health report.
• Explore Compass Therapeutics' analyst forecasts in our growth report.

Microvast Holdings (NasdaqCM:MVST)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Microvast Holdings, Inc. specializes in battery technologies for electric vehicles and energy storage solutions, with a market cap of approximately $376.89 million.

Operations: Microvast Holdings, Inc. has not reported any specific revenue segments.

Market Cap: $376.89M

Microvast Holdings, Inc. reported US$379.8 million in sales for 2024, marking growth from the previous year, but continues to face significant net losses of US$195.46 million, reflecting ongoing unprofitability. Despite a seasoned board and management team with an average tenure of 3.8 and 2 years respectively, the company grapples with high debt levels and share price volatility. However, Microvast's advanced battery technologies showcased at Smart Energy Week 2025 highlight potential strengths in rapid charging and safety features that could appeal to commercial vehicle markets despite financial challenges ahead.

• Dive into the specifics of Microvast Holdings here with our thorough balance sheet health report.
• Gain insights into Microvast Holdings' past trends and performance with our report on the company's historical track record.

Veru (NasdaqCM:VERU)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Veru Inc. is a late clinical stage biopharmaceutical company that develops medicines for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS), with a market cap of $71.74 million.

Operations: Veru Inc. has not reported any specific revenue segments.

Market Cap: $71.74M

Veru Inc., a late-stage biopharmaceutical company with a market cap of US$71.74 million, remains pre-revenue and faces financial hurdles, including less than one year of cash runway and increasing losses over the past five years. Despite being debt-free, Veru's share price is highly volatile, recently receiving an extension from Nasdaq to address its sub-$1 bid price or risk delisting. The company has reported positive Phase 2b clinical trial results for enobosarm in improving body composition among obese patients using GLP-1 receptor agonists like WEGOVY. Analysts anticipate significant stock price appreciation despite current unprofitability challenges.

• Click here and access our complete financial health analysis report to understand the dynamics of Veru.
• Gain insights into Veru's future direction by reviewing our growth report.

Next Steps

• Navigate through the entire inventory of 757 US Penny Stocks here.
• Ready To Venture Into Other Investment Styles? The end of cancer? These 21 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com